IL1B and Other metabolic disease: This forms the basis why new drug candidates, such as natural polyphenols, which prevent IL-1β secretion by inhibiting the function of NLRP3 or other inflammasome components, have lately been under scrutiny in relation to immunological, neurological, and metabolic diseases [37,38].